|
Status |
Public on Dec 31, 2016 |
Title |
KUL_patient_11 |
Sample type |
RNA |
|
|
Source name |
HER2 breast tumor sample
|
Organism |
Homo sapiens |
Characteristics |
tissue: HER2 breast cancer tumor treatment: trastuzumab age: 60 tumor size: 55 nodes positive: 3 er status: 1 pgr status: 1 distant metastasis: 0 time to ddfs: 2544 intratumoral lymphocytic infiltration: 0 stromal lymphocytic infiltration: 1
|
Extracted molecule |
polyA RNA |
Extraction protocol |
RNA was extracted using TRIzol (Life Technologies, Carlsbad, California) following the manufacturer’s instructions. RNA concentration was measured using the NanoDrop 1000 (Thermo Scientific, Waltham, Massachusetts), and RNA integrity (RIN: RNA Integrity Number) was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, California).
|
Label |
biotin
|
Label protocol |
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 100ng total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).
|
|
|
Hybridization protocol |
After purification of the aRNA, 12.5 μg were fragmented and labeled prior to hybridization to the HG-U133_Plus_2 chips.
|
Scan protocol |
GeneChips were scanned using the GeneChip Scanner by Affymetrix.
|
Description |
HER2 breast tumor patient treated with adjuvant trastuzumab
|
Data processing |
The data were analyzed with R-Bioconductor statistical suite. Data were normalized using the fRMA function (affy and fRMA packages)
|
|
|
Submission date |
Jul 01, 2014 |
Last update date |
Jun 13, 2018 |
Contact name |
Sylvain Brohée |
E-mail(s) |
sylvain.brohee@gmail.com
|
Organization name |
Institut Jules Bordet
|
Lab |
Functional Genomics Unit
|
Street address |
Boulevard de Waterloo 127
|
City |
Brussels |
ZIP/Postal code |
1000 |
Country |
Belgium |
|
|
Platform ID |
GPL570 |
Series (1) |
GSE58984 |
Gene profiling of HER2 breast cancer patients treated with adjuvant trastuzumab |
|